vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and RADIANT LOGISTICS, INC (RLGT). Click either name above to swap in a different company.
RADIANT LOGISTICS, INC is the larger business by last-quarter revenue ($232.1M vs $183.1M, roughly 1.3× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 2.3%, a 11.1% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -12.3%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $11.6M). Over the past eight quarters, RADIANT LOGISTICS, INC's revenue compounded faster (12.1% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Radiant Logistics, Inc. is a leading third-party logistics provider offering end-to-end supply chain solutions, domestic and international freight forwarding, warehousing, and last-mile delivery services. It primarily serves North American markets, with key client segments including retail, manufacturing, e-commerce, and industrial sectors, helping businesses optimize logistics workflows and cut operational costs.
AMPH vs RLGT — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $232.1M |
| Net Profit | $24.4M | $5.3M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 3.2% |
| Net Margin | 13.3% | 2.3% |
| Revenue YoY | -1.8% | -12.3% |
| Net Profit YoY | -35.7% | -18.0% |
| EPS (diluted) | $0.51 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $232.1M | ||
| Q3 25 | $191.8M | $226.7M | ||
| Q2 25 | $174.4M | $220.6M | ||
| Q1 25 | $170.5M | $214.0M | ||
| Q4 24 | $186.5M | $264.5M | ||
| Q3 24 | $191.2M | $203.6M | ||
| Q2 24 | $182.4M | $206.0M | ||
| Q1 24 | $171.8M | $184.6M |
| Q4 25 | $24.4M | $5.3M | ||
| Q3 25 | $17.4M | $1.3M | ||
| Q2 25 | $31.0M | $4.9M | ||
| Q1 25 | $25.3M | $2.5M | ||
| Q4 24 | $38.0M | $6.5M | ||
| Q3 24 | $40.4M | $3.4M | ||
| Q2 24 | $37.9M | $4.8M | ||
| Q1 24 | $43.2M | $-703.0K |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 3.2% | ||
| Q3 25 | 13.2% | 0.9% | ||
| Q2 25 | 24.2% | 2.4% | ||
| Q1 25 | 21.9% | 1.6% | ||
| Q4 24 | 24.2% | 3.3% | ||
| Q3 24 | 29.8% | 1.9% | ||
| Q2 24 | 30.3% | 2.4% | ||
| Q1 24 | 27.9% | -0.5% |
| Q4 25 | 13.3% | 2.3% | ||
| Q3 25 | 9.0% | 0.6% | ||
| Q2 25 | 17.8% | 2.2% | ||
| Q1 25 | 14.8% | 1.2% | ||
| Q4 24 | 20.4% | 2.4% | ||
| Q3 24 | 21.1% | 1.7% | ||
| Q2 24 | 20.8% | 2.3% | ||
| Q1 24 | 25.1% | -0.4% |
| Q4 25 | $0.51 | $0.11 | ||
| Q3 25 | $0.37 | $0.03 | ||
| Q2 25 | $0.64 | $0.10 | ||
| Q1 25 | $0.51 | $0.05 | ||
| Q4 24 | $0.74 | $0.13 | ||
| Q3 24 | $0.78 | $0.07 | ||
| Q2 24 | $0.73 | $0.11 | ||
| Q1 24 | $0.81 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $31.9M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $229.8M |
| Total Assets | $1.6B | $439.4M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $31.9M | ||
| Q3 25 | $276.2M | $28.1M | ||
| Q2 25 | $231.8M | $22.9M | ||
| Q1 25 | $236.9M | $19.0M | ||
| Q4 24 | $221.6M | $19.9M | ||
| Q3 24 | $250.5M | $10.4M | ||
| Q2 24 | $217.8M | $24.9M | ||
| Q1 24 | $289.6M | $31.2M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $229.8M | ||
| Q3 25 | $776.7M | $225.7M | ||
| Q2 25 | $757.5M | $226.0M | ||
| Q1 25 | $751.3M | $218.2M | ||
| Q4 24 | $732.3M | $214.4M | ||
| Q3 24 | $727.7M | $212.4M | ||
| Q2 24 | $713.3M | $209.4M | ||
| Q1 24 | $672.4M | $206.0M |
| Q4 25 | $1.6B | $439.4M | ||
| Q3 25 | $1.7B | $445.3M | ||
| Q2 25 | $1.6B | $426.8M | ||
| Q1 25 | $1.6B | $414.5M | ||
| Q4 24 | $1.6B | $386.8M | ||
| Q3 24 | $1.5B | $375.3M | ||
| Q2 24 | $1.5B | $371.2M | ||
| Q1 24 | $1.6B | $364.0M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $12.4M |
| Free Cash FlowOCF − Capex | $24.6M | $11.6M |
| FCF MarginFCF / Revenue | 13.4% | 5.0% |
| Capex IntensityCapex / Revenue | 4.5% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.35× | 2.33× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $8.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $12.4M | ||
| Q3 25 | $52.6M | $2.5M | ||
| Q2 25 | $35.6M | $3.1M | ||
| Q1 25 | $35.1M | $-5.7M | ||
| Q4 24 | $29.0M | $15.7M | ||
| Q3 24 | $60.0M | $205.0K | ||
| Q2 24 | $69.1M | $1.3M | ||
| Q1 24 | $55.3M | $3.9M |
| Q4 25 | $24.6M | $11.6M | ||
| Q3 25 | $47.2M | $977.0K | ||
| Q2 25 | $25.0M | $2.2M | ||
| Q1 25 | $24.4M | $-6.4M | ||
| Q4 24 | $16.6M | $14.1M | ||
| Q3 24 | $46.2M | $-1.9M | ||
| Q2 24 | $63.1M | $-185.0K | ||
| Q1 24 | $46.5M | $1.8M |
| Q4 25 | 13.4% | 5.0% | ||
| Q3 25 | 24.6% | 0.4% | ||
| Q2 25 | 14.3% | 1.0% | ||
| Q1 25 | 14.3% | -3.0% | ||
| Q4 24 | 8.9% | 5.3% | ||
| Q3 24 | 24.1% | -0.9% | ||
| Q2 24 | 34.6% | -0.1% | ||
| Q1 24 | 27.1% | 1.0% |
| Q4 25 | 4.5% | 0.3% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 6.1% | 0.4% | ||
| Q1 25 | 6.3% | 0.3% | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 1.0% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 5.1% | 1.2% |
| Q4 25 | 1.35× | 2.33× | ||
| Q3 25 | 3.03× | 1.90× | ||
| Q2 25 | 1.15× | 0.63× | ||
| Q1 25 | 1.39× | -2.26× | ||
| Q4 24 | 0.76× | 2.43× | ||
| Q3 24 | 1.48× | 0.06× | ||
| Q2 24 | 1.82× | 0.26× | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RLGT
| Transferred Over Time | $201.2M | 87% |
| Other | $25.0M | 11% |
| Value Added Services | $4.2M | 2% |
| Transferred At Point In Time | $1.8M | 1% |
